Mackenzie Financial
KYMR icon

Mackenzie Financial’s Kymera Therapeutics KYMR Stock Holding History

Mackenzie Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,464
Closed -$270K – 1598
2025
Q4 		$270K Buy
+3,464
New +$234K ﹤0.01% 1423

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Mackenzie Financial's KYMR Position: Q1 2026 in Review

Mackenzie Financial sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 3,464 shares — an estimated $270K sold.

Mackenzie Financial first reported a position in KYMR in Q4 2025 and held it in 1 quarter. The position peaked at $270K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Mackenzie Financial reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 3,464 Kymera Therapeutics shares in Q1 2026, an estimated $270K.
  • Mackenzie Financial first reported a position in Kymera Therapeutics in Q4 2025 and held it in 1 quarter.
  • Mackenzie Financial's Kymera Therapeutics position peaked at $270K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.